Josh Cohen (L) and Justin Klee (Amylyx)
After an about-face on a PhIII trial, FDA sets up an adcomm to review controversial ALS drug next month
Following a U-turn from the FDA, the agency’s Peripheral and Central Nervous System Drugs Advisory Committee will meet on March 30 for an all-day teleconference …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
